JLE

Hématologie

MENU

Inhibiteur de check-point : gare à l’anémie hémolytique auto-immune ! Volume 25, numéro 2, Mars-Avril 2019

  • [1] Ansell S.M., Lesokhin A.M., Borrello I. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2014;372:311-319.
  • [2] Moskowitz C.H., Zinzani P.L., Fanale M.A. Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. Blood. 2016;128:1107.
  • [3] Lesokhin A.M., Ansell S.M., Armand P. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. Blood. 2014;124:291.
  • [4] Leaf R.K., Ferreri C., Rangachari D. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune check-point inhibitors. Am J Hematol. 2019;94:563-574. 5
  • [5] Brahmer J.R., Lacchetti C., Schneider B.J. Management of immune-related adverse events in patients treated with immune check-point inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768. 17